日本花2.5亿收购百年中药，就能证明中医有效？硬核逻辑现场“打脸”！

[Key Content Summary] A century-old traditional Chinese medicine (TCM) company was acquired by a Japanese company for approximately 250 million RMB. Is this a genuine investment by capital, or a "lower-dimensional attack" on the efficacy of TCM? This video interview features a "die-hard TCM enthusiast" who attempts to prove the irreplaceable nature of TCM by citing arguments such as "Japan has applied for numerous TCM patents" and "Ryukakusan (a TCM formula) is a cure for chronic pharyngitis." Watch as the host conducts online research, dissects the case layer by layer, and uses hard logic and factual evidence to refute their claims live! [Key Points Summary] Investment does not equal efficacy: Capital acquisitions are commercial profit-making activities. Health products and even unoriginal design processes can be patented. The number of patents cannot be used as the gold standard for clinical efficacy. Reject survivor bias: "Everyone says it works" does not equate to medical effectiveness. Self-limiting diseases (such as mild pharyngitis or a cold) will heal on their own in stages without treatment. The credit for self-healing should not be blindly attributed to throat lozenges or folk remedies. The true standard of medicine: While population reproduction relies on biological instincts, extending human lifespan and improving quality of life depend on rigorous phase III clinical trials and modern medical statistics. I regularly update clips from Hu Chenfeng's live streams. If you enjoy them, please like and subscribe; it means a lot to me, thank you so much! #HuChenfeng #TraditionalChineseMedicine #ChineseHerbalMedicineKnowledge #TraditionalChineseMedicineCulture #Japan